Brenig Therapeutics to Showcase BT-267 Phase 1 Findings at AAN 2026 Brenig Therapeutics is set to present Phase 1 data on BT-267, a promising treatment for neurodegenerative diseases, at the AAN 2026 Annual Meeting.

Brenig Therapeutics to Showcase BT-267 Phase 1 Findings at AAN 2026 #USA #Brenig_Therapeutics #BT-267 #Chicago,_Illinois #AAN_2026

Brenig Therapeutics Unveils Phase 1 Data for BT-267 at AD/PD 2026 and Updates on NLRP3 Inhibitor BT-409 Brenig Therapeutics announces its Phase 1 data for BT-267 targeting Parkinson's disease at AD/PD™ 2026, along with updates on BT-409 for neuroinflammation.

Brenig Therapeutics Unveils Phase 1 Data for BT-267 at AD/PD 2026 and Updates on NLRP3 Inhibitor BT-409 #United_States #Boston #Brenig_Therapeutics #BT-267 #BT-409

Brenig Therapeutics Initiates First Human Trials for Innovative Neurodegenerative Therapy BT-409 Brenig Therapeutics has launched its first human trial for BT-409, a novel NLRP3 inhibitor targeting neurodegenerative diseases, with updates on BT-267.

Brenig Therapeutics Initiates First Human Trials for Innovative Neurodegenerative Therapy BT-409 #USA #Boston #Brenig_Therapeutics #BT-267 #BT-409

Megan McGill Takes the Helm as CEO of Brenig Therapeutics to Drive Innovation in Neurodegenerative Treatments Brenig Therapeutics announces the appointment of Dr. Megan McGill as CEO, focusing on advancements in therapies for neurodegenerative diseases driven by innovative discovery platforms.

Megan McGill Takes the Helm as CEO of Brenig Therapeutics to Drive Innovation in Neurodegenerative Treatments #USA #Somerville #Brenig_Therapeutics #Neurodegenerative_Diseases #Megan_McGill

Brenig Therapeutics Welcomes New Leadership and Expands Pipeline with Innovative Therapies Brenig Therapeutics announces key executive appointments and the expansion of its neurology pipeline with innovative therapies, including Parkinson's treatment.

Brenig Therapeutics Welcomes New Leadership and Expands Pipeline with Innovative Therapies #USA #Parkinson's_Disease #Brenig_Therapeutics #BT-267 #Somerville,_Massachusetts

Brenig Therapeutics Kicks Off First-in-Human Clinical Trial for Innovative Parkinson's Drug BT-267 Brenig Therapeutics has launched a significant clinical trial for BT-267, a cutting-edge LRRK2 inhibitor aimed at treating Parkinson's disease, funded by a recent $65 million investment.

Brenig Therapeutics Kicks Off First-in-Human Clinical Trial for Innovative Parkinson's Drug BT-267 #United_States #Parkinson's_Disease #Brenig_Therapeutics #BT-267 #Dover